Fulgent Genetics (FLGT) Cost of Revenue (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Cost of Revenue data on file, last reported at $49.6 million in Q1 2026.

• Quarterly Cost of Revenue rose 10.04% year-over-year to $49.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $269.9 million (up 8511.81% YoY) and the FY2025 annual result came in at $191.8 million, up 429.15% from the prior year.
• Cost of Revenue fell to $49.6 million in Q1 2026 per FLGT's latest filing, from $159.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $159.4 million in Q4 2025, with the low at -$95.6 million in Q4 2024.
• Average Cost of Revenue over 5 years is $29.6 million, with a median of $12.3 million recorded in 2025.
• Year-over-year, Cost of Revenue surged 1452.02% in 2022 and sank 311.25% in 2024.
• Fulgent Genetics' Cost of Revenue stood at $10.3 million in 2022, then surged by 341.59% to $45.3 million in 2023, then plunged by 311.25% to -$95.6 million in 2024, then soared by 266.66% to $159.4 million in 2025, then sank by 68.85% to $49.6 million in 2026.
• Business Quant data shows FLGT's Cost of Revenue at $49.6 million in Q1 2026, $159.4 million in Q4 2025, and $48.6 million in Q3 2025.